CD19 and diffuse large B-cell lymphoma: Despite excellent clinical results in childhood acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL) and myeloma, current CAR-based approaches are limited to a subset of B-cell antigens [CD19, CD22 (87), B-cell maturation antigen—BCMA (88)].